文献速递细菌感染、耐药与抗菌药物

新型自动化靶向富集方法实现泌尿生殖道及生殖外临床标本中淋病奈瑟菌免培养全基因组测序

Novel approach using automated target enrichment enables culture-independent accurate whole-genome sequencing of Neisseria gonorrhoeae directly from clinical urogenital and extragenital specimens.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

研究纳入113份APTIMA Combo 2淋病奈瑟菌阳性临床标本,其中105份经AM-PCR确认为阳性。对74份循环阈值<20的标本行SureSelectXT HS靶向富集并行Illumina测序,72份(97.3%)成功获得基因组序列;同一解剖部位的配对标本与分离株抗菌药物耐药决定簇及分子流行病学序列型完全一致。

要点

  • 113份淋病奈瑟菌阳性临床标本中105份(92.9%)经AM-PCR确认为阳性。
  • 74份循环阈值<20的标本行靶向富集后,72份(97.3%)成功完成全基因组测序。
  • 同一解剖部位的配对临床标本与分离株的耐药决定簇及序列型完全一致。

核心结论

  • 在Magnis NGS Prep System上自动化的定制SureSelectXT HS靶向富集结合Illumina测序,可实现直接从临床泌尿生殖道及生殖外NAAT标本进行淋病奈瑟菌耐药与分子流行病学的免培养基因组监测。

研究设计与样本

  • 纳入113份淋病奈瑟菌阳性APTIMA Combo 2临床标本(含89株关联淋病奈瑟菌分离株)。
  • DNA用QIAymphony DSP Virus/Pathogen试剂盒提取,AmpliSens多重RT-PCR(AM-PCR)确认105份(92.9%)标本为淋病奈瑟菌阳性。
  • 在Magnis NGS Prep System上使用Magnis SureSelectXT HS Reagent试剂盒构建文库,行Illumina双端测序。

主要发现

  • 105份AM-PCR阳性标本中74份(70.5%)循环阈值<20,接受SureSelectXT HS靶向富集。
  • 全部靶向富集标本中72份(97.3%)成功完成基因组测序。
  • 同一解剖部位的关联APTIMA Combo 2标本与淋病奈瑟菌分离株具有相同的抗菌药物耐药决定簇和分子流行病学序列型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is compromising gonorrhoea treatment, and enhanced N. gonorrhoeae AMR and genome-based epidemiological surveillance is imperative. Molecular tests are replacing N. gonorrhoeae culture internationally, excluding possibilities to perform WGS. We describe and evaluate a novel approach using a custom SureSelectXTHS Target-Enrichment probe panel automated on the Magnis NGS Prep System and Illumina sequencing to generate accurate N. gonorrhoeae genomes directly from clinical urogenital and extragenital specimens. METHODS: One hundred thirteen clinical N. gonorrhoeae-positive APTIMA Combo 2 (AC2) specimens (with 89 linked N. gonorrhoeae isolates) were included. DNA was extracted using QIAsymphony DSP Virus/Pathogen kit. Amplisens multiplex RT-PCR assay (AM-PCR) identified 105 (92.9%) of the AC2 specimens as N. gonorrhoeae positive, which were further examined. Sequence libraries for AC2 specimens were prepared on the Magnis NGS Prep System using the Magnis SureSelectXTHS Reagent kit for Illumina paired-end platforms. Paired-end sequencing was performed on Illumina platforms. RESULTS: Seventy-four of the 105 (70.5%) AC2 samples remained N. gonorrhoeae positive with a cycle threshold <20 in the AM-PCR and subjected to SureSelectXTHS target enrichment and subsequently Illumina WGS. Seventy-two (97.3%) of all target-enriched specimens were successfully genome-sequenced. All linked AC2 specimens and N. gonorrhoeae isolates from the same anatomical site had identical AMR determinants and molecular epidemiological sequence types. CONCLUSIONS: We show that custom SureSelectXTHS target enrichment automated on the Magnis NGS Prep System, followed by Illumina sequencing, enables culture-independent genome-based surveillance of N. gonorrhoeae AMR and molecular epidemiology. This novel methodological advancement provides an efficient and accurate WGS of N. gonorrhoeae directly from clinical urogenital and extragenital NAAT specimens.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Golparian D, Rapp E, Hasmats J, et al. Novel approach using automated target enrichment enables culture-independent accurate whole-genome sequencing of Neisseria gonorrhoeae directly from clinical urogenital and extragenital specimens. J Antimicrob Chemother. 2025. PMID: 39680110. doi:10.1093/jac/dkae446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。